State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Chin Med J (Engl). 2022 Feb 2;135(5):571-583. doi: 10.1097/CM9.0000000000001994.
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
慢性乙型肝炎病毒（HBV）感染仍然是一个全球性的健康负担。及时有效的抗病毒治疗对 HBV 感染患者有益。通过现有的抗病毒药物，包括核苷（酸）类似物和干扰素-α，患者可以实现病毒抑制，改善预后。然而，乙型肝炎表面抗原丢失率较低。为了在慢性乙型肝炎患者中实现功能性治愈甚至完全治愈，需要开发新的抗病毒药物。在这篇综述中，我们总结了现有抗病毒药物的优缺点，并重点介绍了包括直接作用抗病毒药物和免疫治疗方法在内的新型抗病毒药物。
